Seattle、WAにおける肺がんの臨床試験
Seattleとその周辺地域（約30マイル以内）の拠点で、肺がんに関する33件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- 他1件
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
被験者募集中第3相
- Swedish Medical Center-First Hill, Seattle
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
被験者募集中第3相
- Swedish Medical Center-First Hill, Seattle
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
被験者募集中第3相
- University of Washington - Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Swedish Medical Center, Seattle
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
被験者募集中第2/3相
- Fred Hutchinson Cancer Center, Seattle
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
被験者募集中第2相
- Research Site, Seattle
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial
被験者募集中健康なボランティア歓迎
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
被験者募集中第1/2相
- Fred Hutchinson Cancer Research Center, Seattle
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Swedish Medical Center, Seattle
- VA Puget Sound Health Care System, Seattle
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
被験者募集中第1/2相
- Avenzo Therapeutics Recruiting Site, Seattle
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
被験者募集中第3相
- Virginia Mason Medical Center, Seattle
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
被験者募集中
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
被験者募集中第1相
- Xencor Investigative Site, Seattle
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
被験者募集中第1相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
被験者募集中第1/2相
- Fred Hutch Cancer Center, Seattle
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
被験者募集中第1/2相
- Fred Hutchinson Cancer Research Center, Seattle
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
被験者募集中第2相
- Seattle Cancer Care Alliance, Seattle
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
被験者募集中第2相
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Fred Hutchinson Cancer Center, Seattle
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
被験者募集中第2相
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- 他1件
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Virginia Mason Medical Center, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
被験者募集中第2相
- Swedish Medical Center-First Hill, Seattle
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
被験者募集中第1/2相
- Virginia Mason Medical Center, Seattle
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
被験者募集中第1相
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Fred Hutch Cancer Center, Seattle
他の都市における肺がんの試験
- Houston, TX78件の研究
- Boston, MA62件の研究
- New York City, NY60件の研究
- Los Angeles, CA45件の研究
- Washington, DC41件の研究
- Arlington, VA41件の研究
- Chicago, IL41件の研究
- Nashville, TN40件の研究
- Baltimore, MD40件の研究
- St. Louis, MO39件の研究
- Columbus, OH37件の研究
- Philadelphia, PA36件の研究
Seattleにおける他の研究
- 非小細胞肺癌53件の研究
- がん（全種類）49件の研究
- 前立腺がん42件の研究
- 急性骨髄性白血病40件の研究
- 乳がん39件の研究
- 転移性癌39件の研究
- 大腸癌34件の研究
- 卵巣がん30件の研究
- 多発性骨髄腫22件の研究
- 骨髄異形成症候群21件の研究
- 急性リンパ性白血病21件の研究
- 膀胱癌21件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。